Gorilla Glue #4: Potency, Effects, and Patient Suitability

Gorilla Glue #4: What Makes It Exceptional

• Hybrid cross of Chem’s Sister, Sour Dubb, and Chocolate Diesel; balanced 50:50 hybrid
• Among the highest-THC strains available, typically 25–30% — reserved for experienced patients
• Extraordinarily resinous flower; trichome density is a reliable visual indicator of potency
• Dominant terpenes: caryophyllene, myrcene, and limonene — contributing both sedative and uplifting notes

Gorilla Glue #4 (GG4) is one of the most potent cannabis strains available on the UK specialist market. Its extremely high THC content means it occupies a specific clinical niche — it is most appropriate for patients with severe, treatment-resistant pain or those who have already established significant tolerance to cannabis-based medicines. Prescribers must apply heightened scrutiny to patient selection and dose management.

Clinical Indications: Where High Potency Is Justified

• Severe chronic pain unresponsive to standard pharmacological management and lower-potency cannabis
• Cancer pain, particularly neuropathic components that have not responded to opioids or gabapentinoids
• Severe spasticity in MS or spinal cord injury where standard cannabis preparations have been inadequate
• Terminal or palliative care where aggressive symptom management outweighs long-term risk concerns

The decision to prescribe GG4 or similar high-potency preparations should be documented with a clear clinical rationale demonstrating that lower-potency alternatives have been trialled and failed. In a palliative care context, the risk-benefit calculation shifts significantly, and high-potency strains may provide a level of analgesia and comfort that justifies their use even with safety concerns that would preclude prescribing in other contexts.

Risk Assessment and Patient Selection Criteria

• Absolute contraindications: personal or family history of psychotic disorders, unstable cardiovascular disease
• Age: use with caution in patients under 25 due to neurodevelopmental risk; particular caution under 18
• Dependency risk: high-THC preparations carry the highest misuse and dependence potential in the cannabis formulary
• Cognitive function: baseline cognitive assessment recommended; monitor for deterioration at follow-up

GG4’s potency demands a rigorous pre-prescribing assessment. Clinicians must conduct a thorough psychiatric and cardiovascular history, current medications review for interaction risk, and explicit informed consent discussion covering psychoactive effects, driving prohibition, and dependency risk. The prescribing record should reflect the complexity of this assessment.

Dosing High-Potency Cannabis Safely

• Start at 2.5mg THC equivalent maximum — standard starting doses will produce adverse effects in naive patients
• Titrate in 1.25–2.5mg increments with minimum 2-week intervals
• Inhaled route preferred for rapid titration and patient control over dose
• Consider scheduled breaks every 6–8 weeks to assess ongoing need and manage tolerance

Patient education for GG4 must be explicit about the risks of overconsumption. Written materials should describe the signs of acute cannabis toxicity (severe anxiety, paranoia, tachycardia, confusion) and provide clear guidance on what to do if these occur. Patients should have access to a clinical contact point for support between appointments, particularly in the early weeks of prescribing.